Zobrazeno 1 - 10
of 89
pro vyhledávání: '"Hilary M DuBrock"'
Autor:
Steven D Nathan, Hilary M DuBrock, Victor F Tapson, Aaron B Waxman, Karim El-Kersh, Jason Weatherald, Eric Shen, Chunqin Deng, Steven J Cassady, Rahul G Argula, Franz P Rischard, James Tarver, Deborah J Levine, Manisit Das
Publikováno v:
BMJ Open Respiratory Research, Vol 11, Iss 1 (2024)
Background Inhaled treprostinil (iTre) is the only treatment approved for pulmonary hypertension due to interstitial lung disease (PH-ILD) to improve exercise capacity. This post hoc analysis evaluated clinical worsening and PH-ILD exacerbations from
Externí odkaz:
https://doaj.org/article/32e10c17a26f434b9075064fb45b74c9
Publikováno v:
PLoS ONE, Vol 13, Iss 8, p e0201836 (2018)
BACKGROUND:Microvascular inflammation may contribute to the pathogenesis of both heart failure with preserved ejection fraction (HFpEF) and pulmonary hypertension (PH). We investigated whether the inflammation biomarker C-reactive protein (CRP) was a
Externí odkaz:
https://doaj.org/article/a92092a7a84547a68718491f13b87b36
Autor:
Kathryn T. del Valle, MD, Michael J. Krowka, MD, Julie K. Heimbach, MD, Timucin Taner, MD, PhD, Hilary M. DuBrock, MD
Publikováno v:
Transplantation Direct, Vol 8, Iss 12, p e1410 (2022)
Background. Model for end-stage liver disease (MELD) exception criteria for portopulmonary hypertension (POPH) were created to prioritize patients for liver transplant before POPH progression. Little is known about trends in POPH exception frequency,
Externí odkaz:
https://doaj.org/article/94bc6611fd83463c9cab2c2b1a1027db
Autor:
Hilary M. DuBrock, Charles D. Burger, Sonja D. Bartolome, Jeremy P. Feldman, David D. Ivy, Erika B. Rosenzweig, Jeffrey S. Sager, Kenneth W. Presberg, Stephen C. Mathai, Matthew R. Lammi, James R. Klinger, Michael Eggert, Teresa De Marco, Jean M. Elwing, David Badesch, Todd M. Bull, Linda M. Cadaret, Gautam Ramani, Thenappan Thenappan, H. James Ford, Nadine Al‐Naamani, Marc A. Simon, Sula Mazimba, James R. Runo, Murali Chakinala, Evelyn M. Horn, John J. Ryan, Robert P. Frantz, Michael J. Krowka, PHAR Investigators
Publikováno v:
Pulmonary Circulation, Vol 12, Iss 4, Pp n/a-n/a (2022)
Externí odkaz:
https://doaj.org/article/ff7d574098134b25b2891ef16f2df205
Autor:
Kolade M. Agboola, Gurukripa N. Kowlgi, Ibolya Csecs, Hilary M. DuBrock, Hector R. Cajigas, Thomas G. Allison
Publikováno v:
Pulmonary Circulation, Vol 12, Iss 4, Pp n/a-n/a (2022)
Abstract We present a novel description of Bezold–Jarisch Reflex (BJR) during cardiopulmonary exercise testing (CPET) in three young female patients with Group 1 pulmonary arterial hypertension (PAH). These three cases presented within 26 months, r
Externí odkaz:
https://doaj.org/article/41f49ce3bc0e414e8f352cc1a3acdd30
Autor:
Hilary M. DuBrock, Yogesh N. Reddy, Louise A. Durst, Darrell R. Schroeder, Grace Park, Hector R. Cajigas, Garvan C. Kane, Sudhir S. Kushwaha, Robert B. McCully, Joseph G. Murphy, Vidhu Anand, Michael J. Krowka, Robert P. Frantz
Publikováno v:
Pulmonary Circulation, Vol 12, Iss 4, Pp n/a-n/a (2022)
Abstract Pulmonary arterial hypertension (PAH) is a progressive pulmonary vascular disease that negatively impacts health‐related quality of life (HRQOL). The PAH‐symptoms and impact (PAH‐SYMPACT) questionnaire is a validated disease‐specific
Externí odkaz:
https://doaj.org/article/68030dbb18494db9acc5a577b7401d73
Autor:
Kristin B. Highland, Rebecca Crawford, Peter Classi, Ross Morrison, Lynda Doward, Andrew C. Nelsen, Howard Castillo, Stephen C. Mathai, Hilary M. DuBrock
Publikováno v:
Health and Quality of Life Outcomes, Vol 19, Iss 1, Pp 1-13 (2021)
Abstract Background Pulmonary arterial hypertension (PAH) is characterized by progressive limitations on physical activity, right heart failure, and premature death. The World Health Organization functional classification (WHO-FC) is a clinician-rate
Externí odkaz:
https://doaj.org/article/11283abd18d94a0597feda417f3cb989
Autor:
Hilary M. DuBrock, Charles D. Burger, Sonja D. Bartolome, Jeremy P. Feldman, D. Dunbar Ivy, Erika B. Rosenzweig, Jeffrey S. Sager, Kenneth W. Presberg, Stephen C. Mathai, Matthew R. Lammi, James R. Klinger, Michael Eggert, Teresa De Marco, Jean M. Elwing, David Badesch, Todd M. Bull, Linda M. Cadaret, Gautam Ramani, Thenappan Thenappan, H. James Ford, Nadine Al-Naamani, Marc A. Simon, Sula Mazimba, James R. Runo, Murali Chakinala, Evelyn M. Horn, John J. Ryan, Robert P. Frantz, Michael J. Krowka
Publikováno v:
Pulmonary Circulation, Vol 11 (2021)
Compared to idiopathic pulmonary arterial hypertension (IPAH), patients with portopulmonary hypertension (POPH) have worse survival. Health disparities may contribute to these differences but have not been studied. We sought to compare socioeconomic
Externí odkaz:
https://doaj.org/article/0eb2fcb1424a48d382c3a48edad8720f
Autor:
Hilary M. DuBrock, Steven D. Nathan, Bryce B. Reeve, Nicholas A. Kolaitis, Stephen C. Mathai, Peter M. Classi, Andrew C. Nelsen, Bimpe Olayinka-Amao, Lindsey N. Norcross, Susan A. Martin
Publikováno v:
Pulmonary Circulation, Vol 11 (2021)
Pulmonary hypertension resulting from chronic lung disease such as chronic obstructive pulmonary disease and interstitial lung disease is categorized by the World Health Organization as Group 3 pulmonary hypertension. To identify the symptoms and imp
Externí odkaz:
https://doaj.org/article/7f7ef123b3e64bbe9069cf195a017896
Autor:
Aaron Yarlas, Stephen C. Mathai, Steven D. Nathan, Hilary M. DuBrock, Kellie Morland, Natalie Anderson, Mark Kosinski, Xiaochen Lin, Peter Classi
Publikováno v:
Chest. 162:1163-1175
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d5dd2db62b69b737dc38e8b2014c2048
https://doi.org/10.1016/j.chest.2022.08.2206
https://doi.org/10.1016/j.chest.2022.08.2206